한국어
미제공
사전 컨퍼런스 데이
English
한국어
미제공
Explore the Agenda
Pre-Conference Day
Tuesday, 9 June 2026
Day One
Wednesday, 10 June 2026
Day Two
Thursday, 11 June 2026
Bispecific ADCs Day - 이중특이성 ADC 데이
Uncover key scientific and technical updates in the rapidly evolving area of bispecific ADCs
The agenda will address the drivers behind the innovation, as well as the science behind target selection, conjugation strategies, and the manufacturing of bispecific ADCs. Leave with all the knowledge you might need to develop your own successful and clinically viable Bispecific ADC.
This day is intended for researchers currently developing bispecific ADCs and those seeking to expand or initiate research efforts in this area.
* This day is shared with attendees of the 5th World ADC Summit South Korea
Defining Target Selection for Bispecific ADCs to Ensure Efficacy & Therapeutic Impact
9:00 am From Proximity Mapping to Therapeutics: Rational Target-Pair Selection With the MINTTM Platform for Bispecific ADCs
- Explore how MINT™ maps cell-surface protein microenvironments using proximity proteomics and machine learning to identify novel, co-localized target pairs for precision therapeutics
- Outline how applying MINT™ enables rational selection of tumor-associated proximity antigens (TAPAs), guiding the design of bispecific ADCs with improved tumor selectivity and reduced off-target engagement
- Analyze how this proximity-driven framework supports the discovery and optimization of multiple bispecific ADC candidates, providing a systematic path from target-pair identification to preclinical validation
9:30 am Exploring Improving Penetration of Anti-Cancer Drugs Into TME & Designing Bispecific ADCs
- Exploring PMC-403, a novel TIE2 trans binding vessel normalizer in TME
- Introducing PMC-005 (EGFRviii) and PAb-100 (MUC1) and exploring bispecific ADC
- Discussing a hypothesis of PMC-403 and Bispecific ADC targeting EGFRviii and MUC1
10:00 am Morning Break
10:45 am Networking Session
Network with fellow attendees to share scientific insights on bispecific and T-cell engager discovery, development and manufacturing, ahead of the main conference days, as well as with global service providers and those working in the ADC and TPD fields.
Streamlining CMC & Bioanalysis for Bispecific ADCs to Overcome Added Complexity of Different Components & Prevent Downstream Errors
11:30 am Understanding How CMC Processes Differ for Bispecific ADCs & How to Adapt to Them to Reduce Manufacturing Complexity
- Mapping key CMC differences in bispecific ADCs and traditional ADCs to understand how to adapt manufacturing processes
- Implementing flexible process development and control strategies to prevent downstream challenges
- Leveraging platform technologies to reduce complexity and improve product quality
12:00 pm Nanobody-Drug Conjugates: Redefining Precision in Bispecific ADC Design
- Exploring how conventional ADCs suffer from fixed architectures, limiting tumor selectivity and pharmacokinetic control, resulting in off-target toxicity
- Outlining bispecific nanobody-drug conjugates targeting an IO receptor, combined with HSA and a chemotherapeutic, enable simultaneous immune checkpoint engagement and tumor killing
- Explaining how this bispecific design overcomes resistance and systemic toxicity, enhancing drug exposure, pharmacokinetic stability, and safety
12:30 pm Lunch
Balancing Conjugation Chemistry With Bispecific ADC Design & Optimizing Payload Selection to Enhance Stability & Efficacy
1:30 pm ROR1 ADC: AxcynDOTTM Dual Payload Platform
- Exploring a dual-Payload ADC platform for next-generation therapeutics
- Presenting the discovery of anti-ROR1 ADC candidates
- Showcasing preclinical evaluation supporting enhanced anti-tumor activity and overcoming resistance
2:00 pm NEOK002 (ABL209): Redesigning an EGFRxMUC1 Bispecific TOP1i ADC With Promising Anti-Tumor Activity & Enhanced Therapeutic Window
- Introducing the development strategy of NEOK002 and discuss what differentiates it from existing EGFR/MUC1 targeting agents
- Exploring the pharmacological and toxicological characteristics of the differentiated features
- Discussing the clinical development potential secured through various preclinical studies
2:30 pm Beyond Bispecific ADCs & The Next Wave: From Better Delivery to Checkmate Killing
- Exploring the evolution from traditional to bispecific ADCs
- Discussing the internalization-lethality gap and defining the biological ceiling of efficacy
- Predicting the next wave focused on overcoming resistance